Cytosorbents Total Liabilities 2010-2025 | CTSO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytosorbents total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytosorbents total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$229B
Boston Scientific (BSX)	$157.6B
Stryker (SYK)	$150.8B
EssilorLuxottica (ESLOY)	$144B
Medtronic (MDT)	$118.3B
Lonza Group Ag (LZAGY)	$50.6B
Haleon (HLN)	$43.2B
ResMed (RMD)	$41.8B
GE HealthCare Technologies (GEHC)	$33.8B
Agilent Technologies (A)	$33.6B
Koninklijke Philips (PHG)	$26.8B
Terumo (TRUMY)	$26.5B
Insulet (PODD)	$23.4B
Zimmer Biomet Holdings (ZBH)	$21.3B
Smith & Nephew SNATS (SNN)	$16.3B
Baxter (BAX)	$12.6B
Sunny Optical Technology (SNPTF)	$10.8B
Demant (WILYY)	$8.1B
Bio-Rad Laboratories (BIO)	$8B
Lantheus Holdings (LNTH)	$3.8B
Envista Holdings (NVST)	$3.5B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Prestige Consumer Healthcare (PBH)	$3.3B
Perrigo (PRGO)	$3.3B
ICU Medical (ICUI)	$3.1B
Haemonetics (HAE)	$2.7B
LeMaitre Vascular (LMAT)	$2.2B
Acuren (TIC)	$2.2B
Curaleaf Holdings (CURLF)	$2.1B
QuidelOrtho (QDEL)	$1.9B